Lodo Therapeutics Corp.

Lodo Therapeutics Corp.

Lodo Therapeutics Corp.

Overview
Date Founded

2015

Headquarters

430 East 29th Street,New York, NY 10016

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Other Business & Consulting Services
Hospitals & Patient Services
Biotechnology
Holding Companies

Company Description

Lodo Therapeutics Corp. develops novel therapeutics derived from its metagenomics-based small molecule discovery platform. The company was founded by Sean Brady and David L. Pompliano on November 11, 2015 and is headquartered in New York, NY.

Executives & Employees

Co-Founder

Chief Executive Officer & Director

Executive Officer

Executive Officer

Executive Officer

Board of Directors

Co-Founder at Alexandria Real Estate Equities, Inc.

Managing Director at ARCH Venture Partners

Vice President-Corporate Business Development at Eli Lilly & Company

Vice President, Pharmaceutical Discovery at AbbVie, Inc.

Chief Executive Officer & Director at TARA Biosystems, Inc.

Vice President Pfizer Venture Investments at Pfizer, Inc.

President & Chief Executive Officer at Rodeo Therapeutics Corp.

Vice President-Venture Investments at Johnson & Johnson Innovation JJDC, Inc.

Paths to Lodo Therapeutics Corp.
Potential Connections via
Relationship Science
You
Lodo Therapeutics Corp.
Recent Transactions
Details Hidden

Lodo Therapeutics Corp. raised money in a private placement transaction

Investors
Details Hidden

Harris & Harris focuses on investing in early-stage tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). They look for companies that have solid management, proprietary technology, a product or service that meets a real need and a significant market. They consider ease of market entry and how challenging it may be for a company to secure customers. Start-ups should have the ability to attract additional investment, in later rounds of venture capital financing or through an IPO or acquisition. Harris & Harris may hold their investments for 7 years or more.

Details Hidden

Abbvie Biotech investments address critical needs in oncology, immunology, and neuroscience companies based in the US and Europe. The firm provides financing for Seed or Series A stage, they have the capability and flexibility to lead or co-lead a syndicate.

Details Hidden

Accelerator Corp. invests in emerging life sciences opportunities. Through the global activities of their affiliates, the firm has access to new technologies and commercial opportunities developed at leading research institutions, universities and biotechnology companies around the world. Accelerator Corp. looks for companies that are milestone-driven and have a set of objectives designed to advance novel technologies rapidly from discovery to a proof-of-concept development stage that supports further financing.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Lodo Therapeutics Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Lodo Therapeutics Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Lodo Therapeutics Corp..